Mark D. Perrin
Plus aucun poste en cours
Profil
Mark D.
Perrin formerly worked at ConjuChem Biotechnologies, Inc., as President & Chief Executive Officer from 2005 to 2009, InVivo Therapeutics Corp., as Chairman & Chief Executive Officer, ConjuChem Biotechnologies, Inc., as President & Chief Executive Officer in 2005, Invivo Therapeutics Holdings Corp., as Chairman & Chief Executive Officer from 2014 to 2017, COR Therapeutics, Inc., as Executive Vice President-Commercial Operations from 1995 to 2001, Orphan Medical, Inc., as Chief Commercial Officer & Executive VP from 2002 to 2005, Lederle Laboratories, as Division Manager-Lederle Canada, Burroughs Wellcome, as Vice President-Marketing & Sales, and Dennan Consulting, as President.
Mr. Perrin received his undergraduate degree from Fordham University and Masters Business Admin degree from Kellogg School of Management.
Anciens postes connus de Mark D. Perrin
| Sociétés | Poste | Fin |
|---|---|---|
| INVIVO THERAPEUTICS HOLDINGS CORP. | Directeur Général | 18/12/2017 |
| Dennan Consulting | President | 01/01/2014 |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | President | 31/08/2009 |
Orphan Medical, Inc.
 Orphan Medical, Inc. Pharmaceuticals: MajorHealth Technology Orphan Medical, Inc. develops and markets pharmaceutical and health care products. The company was founded in 1993 and is located in Minnetonka, MN. | Corporate Officer/Principal | 01/01/2005 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | 01/01/2001 |
Formation de Mark D. Perrin
| Fordham University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| Entreprise privées | 8 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Orphan Medical, Inc.
Orphan Medical, Inc. Pharmaceuticals: MajorHealth Technology Orphan Medical, Inc. develops and markets pharmaceutical and health care products. The company was founded in 1993 and is located in Minnetonka, MN. | Health Technology |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
InVivo Therapeutics Corp.
 InVivo Therapeutics Corp. BiotechnologyHealth Technology InVivo Therapeutics Corp. operates as a medical device company that develops groundbreaking technologies for the treatment of spinal cord injuries. The company was founded by Joseph P. Vacanti and Robert S. Langer, Jr. in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Lederle Laboratories
 Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Commercial Services |
| Burroughs Wellcome | |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
| Dennan Consulting |